1. < Home

2021

Theo, Thesing, Feldmann Carsten, and Burchardt Martin. "Agile Versus Waterfall Project Management: Decision Model for Selecting the Appropriate Approach to a Project." Procedia Computer Science 181 (2021): 746-56. https://doi.org/https://doi.org/10.1016/j.procs.2021.01.227. https://www.sciencedirect.com/science/article/pii/S1877050921002702

Xu, B., L. Tian, J. Chen, J. Wang, R. Ma, W. Dong, A. Li, et al. "An Oncolytic Virus Expressing a Full-Length Antibody Enhances Antitumor Innate Immune Response to Glioblastoma." Nat Commun 12, no. 1 (Oct 8 2021): 5908. https://doi.org/10.1038/s41467-021-26003-6. https://www.ncbi.nlm.nih.gov/pubmed/34625564

Yu, S., S. Wei, M. Savani, X. Lin, K. Du, I. Mender, S. Siteni, et al. "A Modified Nucleoside 6-Thio-2'-Deoxyguanosine Exhibits Antitumor Activity in Gliomas." Clin Cancer Res 27, no. 24 (Dec 15 2021): 6800-14. https://doi.org/10.1158/1078-0432.CCR-21-0374. https://www.ncbi.nlm.nih.gov/pubmed/34593527

2022

Ganesa, S., A. Sule, R. K. Sundaram, and R. S. Bindra. "Mismatch Repair Proteins Play a Role in Atr Activation Upon Temozolomide Treatment in Mgmt-Methylated Glioblastoma." [In eng]. Sci Rep 12, no. 1 (Apr 6 2022): 5827. https://doi.org/10.1038/s41598-022-09614-x

Lin, K., S. E. Gueble, R. K. Sundaram, E. D. Huseman, R. S. Bindra, and S. B. Herzon. "Mechanism-Based Design of Agents That Selectively Target Drug-Resistant Glioma." [In eng]. Science 377, no. 6605 (Jul 29 2022): 502-11. https://doi.org/10.1126/science.abn7570

Liu, Shunan, Yanyan Song, Ian Y. Zhang, Leying Zhang, Hang Gao, Yanping Su, Yihang Yang, et al. "Rage Inhibitors as Alternatives to Dexamethasone for Managing Cerebral Edema Following Brain Tumor Surgery." Neurotherapeutics 19, no. 2 (2022): 635-48. https://doi.org/10.1007/s13311-022-01207-w. https://doi.org/10.1007/s13311-022-01207-w

Low, J. T., V. Chandramohan, M. L. Bowie, M. C. Brown, M. S. Waitkus, A. Briley, K. Stevenson, et al. "Epigenetic Sting Silencing Is Developmentally Conserved in Gliomas and Can Be Rescued by Methyltransferase Inhibition." Cancer Cell 40, no. 5 (May 9 2022): 439-40. https://doi.org/10.1016/j.ccell.2022.04.009. https://www.ncbi.nlm.nih.gov/pubmed/35487217

Oh, J. H., E. A. Power, W. Zhang, D. J. Daniels, and W. F. Elmquist. "Murine Central Nervous System and Bone Marrow Distribution of the Aurora a Kinase Inhibitor Alisertib: Pharmacokinetics and Exposure at the Sites of Efficacy and Toxicity." [In eng]. J Pharmacol Exp Ther 383, no. 1 (Oct 2022): 44-55. https://doi.org/10.1124/jpet.122.001268

Shi, D. D., M. R. Savani, M. M. Levitt, A. C. Wang, J. E. Endress, C. E. Bird, J. Buehler, et al. "De Novo Pyrimidine Synthesis Is a Targetable Vulnerability in Idh Mutant Glioma." Cancer Cell 40, no. 9 (Sep 12 2022): 939-56 e16. https://doi.org/10.1016/j.ccell.2022.07.011. https://www.ncbi.nlm.nih.gov/pubmed/35985343

Stewart, C. E., M. E. Guerra-García, L. Luo, N. T. Williams, Y. Ma, J. A. Regal, D. Ghosh, et al. "The Effect of Atm Loss on Radiosensitivity of a Primary Mouse Model of Pten-Deleted Brainstem Glioma." [In eng]. Cancers (Basel) 14, no. 18 (Sep 17 2022). https://doi.org/10.3390/cancers14184506

Talele, S., W. Zhang, J. Chen, S. K. Gupta, D. M. Burgenske, J. N. Sarkaria, and W. F. Elmquist. "Central Nervous System Distribution of the Ataxia-Telangiectasia Mutated Kinase Inhibitor Azd1390: Implications for the Treatment of Brain Tumors." [In eng]. J Pharmacol Exp Ther 383, no. 1 (Oct 2022): 91-102. https://doi.org/10.1124/jpet.122.001230

Tian, L., B. Xu, Y. Chen, Z. Li, J. Wang, J. Zhang, R. Ma, et al. "Specific Targeting of Glioblastoma with an Oncolytic Virus Expressing a Cetuximab-Ccl5 Fusion Protein Via Innate and Adaptive Immunity." Nat Cancer 3, no. 11 (Nov 2022): 1318-35. https://doi.org/10.1038/s43018-022-00448-0. https://www.ncbi.nlm.nih.gov/pubmed/36357700

Zhang, Ian Y, Shunan Liu, Leying Zhang, Rongrui Liang, Qingxiao Fang, Jie Zhao, Lyuzhi Ren, et al. "Rage Ablation Attenuates Glioma Progression and Enhances Tumor Immune Responses by Suppressing Galectin-3 Expression." Neuro-Oncology 25, no. 5 (2022): 886-98. https://doi.org/10.1093/neuonc/noac250. https://doi.org/10.1093/neuonc/noac250

2023

Arrieta, V. A., C. Dmello, D. J. McGrail, D. J. Brat, C. Lee-Chang, A. B. Heimberger, D. Chand, R. Stupp, and A. M. Sonabend. "Immune Checkpoint Blockade in Glioblastoma: From Tumor Heterogeneity to Personalized Treatment." J Clin Invest 133, no. 2 (Jan 17 2023). https://doi.org/10.1172/JCI163447. https://www.ncbi.nlm.nih.gov/pubmed/36647828

Arrieta, V. A., J. Duerinck, K. B. Burdett, K. J. Habashy, W. Geens, A. Gould, J. K. Schwarze, et al. "Erk1/2 Phosphorylation Predicts Survival in Recurrent Glioblastoma Following Intracerebral and Adjuvant Pd-1/Ctla-4 Immunotherapy: A Remark-Guided Analysis." Clin Cancer Res  (Nov 8 2023). https://doi.org/10.1158/1078-0432.CCR-23-1889. https://www.ncbi.nlm.nih.gov/pubmed/37939133

Dmello, C., J. Zhao, L. Chen, A. Gould, B. Castro, V. A. Arrieta, D. Y. Zhang, et al. "Checkpoint Kinase 1/2 Inhibition Potentiates Anti-Tumoral Immune Response and Sensitizes Gliomas to Immune Checkpoint Blockade." Nat Commun 14, no. 1 (Mar 22 2023): 1566. https://doi.org/10.1038/s41467-023-36878-2. https://www.ncbi.nlm.nih.gov/pubmed/36949040

Gould, A., V. A. A. Gonzales, C. C. Dmello, R. Saganty, R. V. Lukas, D. Y. Zhang, A. B. Heimberger, et al. "Advances in Blood-Brain Barrier Disruption to Facilitate Drug Delivery for Infiltrative Gliomas." Adv Oncol 3, no. 1 (May 2023): 77-86. https://doi.org/10.1016/j.yao.2023.01.017. https://www.ncbi.nlm.nih.gov/pubmed/37860079

Hanahan, D., and M. Monje. "Cancer Hallmarks Intersect with Neuroscience in the Tumor Microenvironment." Cancer Cell 41, no. 3 (Mar 13 2023): 573-80. https://doi.org/10.1016/j.ccell.2023.02.012. https://www.ncbi.nlm.nih.gov/pubmed/36917953

Hong, B., U. Sahu, M. P. Mullarkey, E. Hong, G. Pei, Y. Yan, Y. Otani, et al. "Pkr Induces Tgf-Beta and Limits Oncolytic Immune Therapy." J Immunother Cancer 11, no. 2 (Feb 2023). https://doi.org/10.1136/jitc-2022-006164. https://www.ncbi.nlm.nih.gov/pubmed/36796878

Krishna, S., A. Choudhury, M. B. Keough, K. Seo, L. Ni, S. Kakaizada, A. Lee, et al. "Glioblastoma Remodelling of Human Neural Circuits Decreases Survival." Nature 617, no. 7961 (May 2023): 599-607. https://doi.org/10.1038/s41586-023-06036-1. https://www.ncbi.nlm.nih.gov/pubmed/37138086

Ma, R., Z. Li, E. A. Chiocca, M. A. Caligiuri, and J. Yu. "The Emerging Field of Oncolytic Virus-Based Cancer Immunotherapy." Trends Cancer 9, no. 2 (Feb 2023): 122-39. https://doi.org/10.1016/j.trecan.2022.10.003. https://www.ncbi.nlm.nih.gov/pubmed/36402738

Mahdi, J., J. Dietrich, K. Straathof, C. Roddie, B. J. Scott, T. B. Davidson, L. M. Prolo, et al. "Tumor Inflammation-Associated Neurotoxicity." Nat Med 29, no. 4 (Apr 2023): 803-10. https://doi.org/10.1038/s41591-023-02276-w. https://www.ncbi.nlm.nih.gov/pubmed/37024595

Mancusi, R., and M. Monje. "The Neuroscience of Cancer." Nature 618, no. 7965 (Jun 2023): 467-79. https://doi.org/10.1038/s41586-023-05968-y. https://www.ncbi.nlm.nih.gov/pubmed/37316719

Pellot Ortiz, K. I., J. S. Rechberger, L. F. Nonnenbroich, D. J. Daniels, and J. N. Sarkaria. "Mdm2 Inhibition in the Treatment of Glioblastoma: From Concept to Clinical Investigation." [In eng]. Biomedicines 11, no. 7 (Jul 2 2023). https://doi.org/10.3390/biomedicines11071879

Rahman, R., M. C. Polley, L. Alder, P. K. Brastianos, C. K. Anders, H. A. Tawbi, M. Mehta, et al. "Current Drug Development and Trial Designs in Neuro-Oncology: Report from the First American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials Conference." [In eng]. Lancet Oncol 24, no. 4 (Apr 2023): e161-e71. https://doi.org/10.1016/s1470-2045(23)00005-0

Taylor, K. R., T. Barron, A. Hui, A. Spitzer, B. Yalçin, A. E. Ivec, A. C. Geraghty, et al. "Glioma Synapses Recruit Mechanisms of Adaptive Plasticity." [In eng]. Nature 623, no. 7986 (Nov 2023): 366-74. https://doi.org/10.1038/s41586-023-06678-1

Taylor, K. R., and M. Monje. "Neuron-Oligodendroglial Interactions in Health and Malignant Disease." Nat Rev Neurosci 24, no. 12 (Dec 2023): 733-46. https://doi.org/10.1038/s41583-023-00744-3. https://www.ncbi.nlm.nih.gov/pubmed/37857838

Tu, K. J., C. E. Stewart, P. G. Hendrickson, J. A. Regal, S. Y. Kim, D. M. Ashley, M. S. Waitkus, and Z. J. Reitman. "Pooled Genetic Screens to Identify Vulnerabilities in Tert-Promoter-Mutant Glioblastoma." [In eng]. Oncogene 42, no. 44 (Oct 2023): 3274-86. https://doi.org/10.1038/s41388-023-02845-w

Weidenhammer, L. B., H. Q. Liu, L. Luo, N. T. Williams, K. Deland, D. G. Kirsch, and Z. J. Reitman. "Inducing Primary Brainstem Gliomas in Genetically Engineered Mice Using Rcas/Tva Retroviruses and Cre/Loxp Recombination." [In eng]. STAR Protoc 4, no. 1 (Mar 17 2023): 102094. https://doi.org/10.1016/j.xpro.2023.102094

Winkler, F., H. S. Venkatesh, M. Amit, T. Batchelor, I. E. Demir, B. Deneen, D. H. Gutmann, et al. "Cancer Neuroscience: State of the Field, Emerging Directions." Cell 186, no. 8 (Apr 13 2023): 1689-707. https://doi.org/10.1016/j.cell.2023.02.002. https://www.ncbi.nlm.nih.gov/pubmed/37059069

Zhang, W., J. H. Oh, W. Zhang, S. Rathi, J. D. Larson, R. J. Wechsler-Reya, R. W. Sirianni, and W. F. Elmquist. "Central Nervous System Distribution of Panobinostat in Preclinical Models to Guide Dosing for Pediatric Brain Tumors." [In eng]. J Pharmacol Exp Ther 387, no. 3 (Dec 2023): 315-27. https://doi.org/10.1124/jpet.123.001826

Zhang, W., J. H. Oh, W. Zhang, S. Rathi, J. Le, S. Talele, J. N. Sarkaria, and W. F. Elmquist. "How Much Is Enough? Impact of Efflux Transporters on Drug Delivery Leading to Efficacy in the Treatment of Brain Tumors." [In eng]. Pharm Res 40, no. 11 (Nov 2023): 2731-46. https://doi.org/10.1007/s11095-023-03574-1

2024

Chen, J., D. J. Laverty, S. Talele, A. Bale, B. L. Carlson, K. A. Porath, K. K. Bakken, et al. "Aberrant Atm Signaling and Homology-Directed DNA Repair as a Vulnerability of P53-Mutant Gbm to Azd1390-Mediated Radiosensitization." [In eng]. Sci Transl Med 16, no. 734 (Feb 14 2024): eadj5962. https://doi.org/10.1126/scitranslmed.adj5962

Floyd, W., D. Carpenter, E. Vaios, R. Shenker, P. Hendrickson, J. D. Adamson, W. M. Giles, et al. "Effects of Ataxia-Telangiectasia Mutated Variants on Radionecrosis and Local Control after Stereotactic Radiation Surgery for Non-Small Cell Lung Cancer Brain Metastases." [In eng]. Adv Radiat Oncol 9, no. 1 (Jan 2024): 101320. https://doi.org/10.1016/j.adro.2023.101320

Hao, Y. H., N. Borenstein-Auerbach, A. Grichuk, L. Li, M. C. Lafita-Navarro, S. Fang, P. Nogueira, et al. "Myc-Mediated Inhibition of Arnt2 Uncovers a Key Tumor Suppressor in Glioblastoma." [In eng]. Res Sq  (Aug 15 2024). https://doi.org/10.21203/rs.3.rs-4810280/v1

Huseman, E. D., A. Lo, O. Fedorova, J. L. Elia, S. E. Gueble, K. Lin, R. K. Sundaram, et al. "Mechanism of Action of Kl-50, a Candidate Imidazotetrazine for the Treatment of Drug-Resistant Brain Cancers." [In eng]. J Am Chem Soc 146, no. 27 (Jul 10 2024): 18241-52. https://doi.org/10.1021/jacs.3c06483

Jain, S., J. I. Griffith, K. A. Porath, S. Rathi, J. Le, T. I. Pasa, P. A. Decker, et al. "Bystander Effects, Pharmacokinetics, and Linker-Payload Stability of Egfr-Targeting Antibody-Drug Conjugates Losatuxizumab Vedotin and Depatux-M in Glioblastoma Models." [In eng]. Clin Cancer Res 30, no. 15 (Aug 1 2024): 3287-97. https://doi.org/10.1158/1078-0432.Ccr-24-0426

Ji, J., S. Dragojevic, C. M. Callaghan, E. J. Smith, S. Talele, W. Zhang, M. A. Connors, et al. "Differential Distribution of the DNA-Pkcs Inhibitor Peposertib Selectively Radiosensitizes Patient-Derived Melanoma Brain Metastasis Xenografts." [In eng]. Mol Cancer Ther 23, no. 5 (May 2 2024): 662-71. https://doi.org/10.1158/1535-7163.Mct-23-0552

Kim, J. J., I. K. Schaeffner, D. E. Heppner, C. To, P. A. Jänne, T. S. Beyett, and M. J. Eck. "A Constitutive Egfr Kinase Dimer to Study Inhibitor Pharmacology." [In eng]. Mol Pharmacol 105, no. 2 (Jan 10 2024): 97-103. https://doi.org/10.1124/molpharm.123.000768

Low, J. T., M. C. Brown, Z. J. Reitman, J. D. Bernstock, J. M. Markert, G. K. Friedman, M. S. Waitkus, M. L. Bowie, and D. M. Ashley. "Understanding and Therapeutically Exploiting Cgas/Sting Signaling in Glioblastoma." [In eng]. J Clin Invest 134, no. 2 (Jan 16 2024). https://doi.org/10.1172/jci163452

Rathi, S., A. C. Mladek, J. H. Oh, S. Dragojevic, D. M. Burgenske, W. Zhang, S. Talele, et al. "Factors Influencing the Central Nervous System (Cns) Distribution of the Ataxia Telangiectasia Mutated and Rad3-Related Inhibitor Elimusertib (Bay1895344): Implications for the Treatment of Cns Tumors." [In eng]. J Pharmacol Exp Ther 391, no. 2 (Oct 18 2024): 346-60. https://doi.org/10.1124/jpet.123.002002

Rathi, S., J. H. Oh, W. Zhang, A. C. Mladek, D. A. Garcia, Z. Xue, D. M. Burgenske, et al. "Preclinical Systemic Pharmacokinetics, Dose Proportionality, and Central Nervous System Distribution of the Atm Inhibitor Wsd0628, a Novel Radiosensitizer for the Treatment of Brain Tumors." [In eng]. J Pharmacol Exp Ther 390, no. 2 (Jul 18 2024): 260-75. https://doi.org/10.1124/jpet.123.001971

Siteni, S., A. Grichuk, and J. W. Shay. "Telomerase in Cancer Therapeutics." [In eng]. Cold Spring Harb Perspect Biol 16, no. 12 (Dec 2 2024). https://doi.org/10.1101/cshperspect.a041703

Taylor, B., N. Tang, Y. Hao, M. Lee, S. Peng, R. Bybee, L. Hartman, et al. "Glioblastoma Vulnerability to Neddylation Inhibition Is Dependent on Pten Status, and Dysregulation of the Cell Cycle and DNA Replication." [In eng]. Neurooncol Adv 6, no. 1 (Jan-Dec 2024): vdae104. https://doi.org/10.1093/noajnl/vdae104

Wu, M. J., H. Kondo, A. V. Kammula, L. Shi, Y. Xiao, S. Dhiab, Q. Xu, et al. "Mutant Idh1 Inhibition Induces Dsdna Sensing to Activate Tumor Immunity." [In eng]. Science 385, no. 6705 (Jul 12 2024): eadl6173. https://doi.org/10.1126/science.adl6173

Zhang, W., J. H. Oh, W. Zhang, C. C. Aldrich, R. W. Sirianni, and W. F. Elmquist. "Pharmacokinetics of Panobinostat: Interspecies Difference in Metabolic Stability." [In eng]. J Pharmacol Exp Ther 389, no. 1 (Mar 15 2024): 96-105. https://doi.org/10.1124/jpet.123.002051

Zhang, W., R. A. Vaubel, J. H. Oh, A. C. Mladek, S. Talele, W. Zhang, K. L. Waller, et al. "Delivery Versus Potency in Treating Brain Tumors: Bi-907828, a Mdm2-P53 Antagonist with Limited Bbb Penetration but Significant in Vivo Efficacy in Glioblastoma." [In eng]. Mol Cancer Ther 23, no. 1 (Jan 3 2024): 47-55. https://doi.org/10.1158/1535-7163.Mct-23-0217

2025

Garcia, D. A., S. Rathi, M. A. Connors, M. Grams, R. A. Vaubel, K. K. Bakken, L. L. Ott, et al. "Modeling the Acute Mucosal Toxicity of Fractionated Radiotherapy Combined with the Atm Inhibitor Wsd0628." [In eng]. Mol Cancer Ther 24, no. 2 (Feb 4 2025): 299-309. https://doi.org/10.1158/1535-7163.Mct-24-0664

Rendo, V., E. Q. Lee, C. Bossi, N. Khuu, M. A. Rudek, S. Pal, N. Azazmeh, et al. "A Window-of-Opportunity Trial Reveals Mechanisms of Response and Resistance to Navtemadlin in Patients with Recurrent Glioblastoma." [In eng]. Sci Transl Med 17, no. 786 (Feb 19 2025): eadn6274. https://doi.org/10.1126/scitranslmed.adn6274